Psoriatic Immune Response to Tildrakizumab

• Status: Not yet recruiting
• Trial end date: 2025-09-01

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

• Phase: Phase 4

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: Sun Pharmaceutical Industries Limited
• Treatments: Antibodies, Monoclonal